Peñas-Lledó Eva M, Dorado Pedro, Cáceres Macarena C, de la Rubia Alfredo, Llerena Adrián
CICAB Clinical Research Centre, Servicio Extremeño de Salud, Extremadura University Hospital, Badajoz, Spain and Faculty of Medicine, University of Extremadura, Badajoz, Spain.
Clin Chem Lab Med. 2007;45(7):835-8. doi: 10.1515/CCLM.2007.181.
An involvement of serotonin receptor 2A (5-HT2A) in the aetiology of schizophrenia has been hypothesised. The 5-HT2A receptor also appears to be an important site of action of atypical antipsychotic drugs. Indeed, association between schizophrenia and the T102C silent polymorphism of the 5-HTR2A gene has been reported. Another polymorphism in the promoter region of 5-HTR2A (A-1438G) in linkage disequilibrium with the T102C polymorphism has also been reported. It has been suggested that the A-1438G polymorphism alters promoter activity and expression of 5-HT2A receptors and might be responsible for the associations with schizophrenia and the efficacy of atypical antipsychotics such as risperidone.
We analysed the 5-HTR2A T102C and A-1438G polymorphisms in clinically stable schizophrenia patients (SPs) and healthy volunteers (HVs). We developed an allele-specific PCR-based restriction fragment length polymorphism (PCR-RFLP) method. In SPs, we also described differences across both diagnosis subtypes (paranoid vs. non-paranoid) and antipsychotic drug treatment (risperidone vs. other classical antipsychotic drugs).
Two groups of 114 SPs and 142 HVs were studied. The frequency of the 5-HTR2A -1438A allele was higher in SPs than in HVs (0.54 vs. 0.44; p<0.05). The frequency of the 102T allele was also higher among SPs than HVs (0.56 vs. 0.46; p<0.05). These two polymorphisms were in linkage disequilibrium. The percentage of carriers of the 1438A/A and 102T/T alleles was 26% and 15% for SPs and HVs, respectively (p<0.05; odds ratio 1.9). No differences in genotype or allele frequencies were found between paranoid and non-paranoid SPs or between SPs on risperidone and those on classical antipsychotic treatment.
The present study demonstrates a higher frequency of 5-HTR2A -1438A and 102T alleles in SPs compared to HVs.
已有假说认为血清素受体2A(5-HT2A)参与了精神分裂症的病因学。5-HT2A受体似乎也是非典型抗精神病药物的一个重要作用位点。确实,已有报道称精神分裂症与5-HTR2A基因的T102C沉默多态性之间存在关联。另一种与T102C多态性处于连锁不平衡状态的5-HTR2A启动子区域多态性(A-1438G)也有报道。有人提出A-1438G多态性会改变5-HT2A受体的启动子活性和表达,可能与精神分裂症以及利培酮等非典型抗精神病药物的疗效相关。
我们分析了临床稳定的精神分裂症患者(SPs)和健康志愿者(HVs)的5-HTR2A T102C和A-1438G多态性。我们开发了一种基于等位基因特异性聚合酶链反应的限制性片段长度多态性(PCR-RFLP)方法。在精神分裂症患者中,我们还描述了两种诊断亚型(偏执型与非偏执型)以及抗精神病药物治疗(利培酮与其他经典抗精神病药物)之间的差异。
研究了两组对象,114名精神分裂症患者和142名健康志愿者。精神分裂症患者中5-HTR2A -1438A等位基因的频率高于健康志愿者(0.54对0.44;p<0.05)。102T等位基因在精神分裂症患者中的频率也高于健康志愿者(0.56对0.46;p<0.05)。这两种多态性处于连锁不平衡状态。1438A/A和102T/T等位基因携带者的百分比在精神分裂症患者和健康志愿者中分别为26%和15%(p<0.05;优势比1.9)。在偏执型和非偏执型精神分裂症患者之间,以及使用利培酮的精神分裂症患者和使用经典抗精神病药物治疗的患者之间,未发现基因型或等位基因频率有差异。
本研究表明,与健康志愿者相比,精神分裂症患者中5-HTR2A -1438A和102T等位基因的频率更高。